Last updated: 2026-09-24 20:42:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
YD Bio Limited (YDES) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $4.69, with a market capitalization of $199.78M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.70 to $22.00. This page covers its latest market performance, valuation, price trends and company information.
$199.78M | |
$3.26 | |
$25.00 | |
$1.70 | |
$3.23 | |
3.08M | |
279.78K | |
-- | |
$22.00 | |
$1.70 | |
-- | |
-- |
YD Bio Limited (YDES) is trading at $4.74 in after-hours trading as of 2026-09-24 20:41:00, up 46.87% ($1.51) from the regular-session close of $3.23.
After-hours trading shows how investors are pricing YDES after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, YD Bio Limited (YDES) moved from $3.95 to $4.69, representing a gain of 18.73% ($0.74).
The stock traded between $2.42 and $5.35 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 553.91 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 14.7%
YDES is currently trading at $4.69, placing it 14.7% of the way from its 52-week low of $1.70 to its 52-week high of $22.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.
| Employees | 15 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of YD Bio Limited (YDES) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.